Endogenous neutrophil-derived HOCl exerts broad antimicrobial and anti-inflammatory activity, with optimal potency at pH 4–6; degradation shifts to less active hypochlorite.
Randomized split-face data in mild–moderate acne show reduced inflammatory lesions with 0.005% NaOCl; AD and chronic-wound literature supports S. aureus reduction and healing.
Claims that sprays replace retinoids, benzoyl peroxide, antibiotics, or biologics lack evidence, particularly for severe nodulocystic acne; rosacea and seborrheic dermatitis data remain limited.
Clinical performance depends on verified concentration (ppm), FDA-cleared topical indications, and packaging that preserves stability; heat, light, and post-opening time can inactivate active HOCl.
Post-procedure use is favored because HOCl is antimicrobial yet less cytotoxic than alcohol-based antiseptics; counsel patients to use it adjunctively and store in opaque containers.
SHOW MORE
Can misting hypochlorous acid every day improve skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Advertisement
From viral skin care hacks to trendy treatment devices, social media is shaping the questions patients bring into the exam room every day. In Dermatology Times’ new weekly series, Social Media Mythbusters, we break down trending claims clinicians are hearing in practice—exploring the proposed mechanism, what the evidence shows (or doesn’t), and whether each trend holds up under scrutiny.
In this edition, we’re examining hypochlorous acid sprays and their impact on skin sensitivity and clarity.
Have a social media trend you’d like us to investigate next? Send us the social media myths your patients are asking about, and we may feature them in an upcoming edition. Connect with us on our social media or email us at [email protected].
The Trend
Few skin care ingredients have made the leap from hospital wound cart to bathroom shelf faster than hypochlorous acid (HOCl). Originally used as a surgical site irrigant and wound care agent, HOCl sprays began appearing in aesthetician offices post-procedure, then crossed into consumer skin care around 2022–2023, and are now a TikTok mainstay. Influencers hold up $15–$40 spray bottles and describe HOCl as "what your white blood cells make to fight bacteria," a "natural antiseptic that heals without disrupting your skin," and the solution for everything from acne and rosacea to perioral dermatitis, eczema flares, and post-workout breakouts.
The market has responded accordingly: the global HOCl sanitizing spray market reached $1.42 billion in 2024 and is projected to nearly triple by 2033. At least 8 branded HOCl formulations have received FDA 510(k) clearance for topical wound management in the past decade, and as of September 2025, dermatology brands like CLn have launched FDA-cleared HOCl sprays specifically marketed for sensitive and irritated skin.
Unlike many viral skin care trends, HOCl has a substantial and legitimate clinical literature behind it. The challenge for dermatologists is separating the documented mechanisms and evidence-backed indications from the hyperbole, and addressing the real-world formulation and stability issues that complicate patient use
HOCl is endogenously produced by neutrophils via the myeloperoxidase-catalyzed oxidation of chloride ions during the oxidative burst of innate immune responses. It is the active species deployed by white blood cells to destroy invading pathogens—a fact that social media has correctly grasped, even if the downstream claims are sometimes inflated. HOCl is most biologically active at mildly acidic to neutral pH (4.0–6.0), where the HOCl species predominates over hypochlorite (OCl⁻). Consumer formulations that drift outside this range due to instability, improper storage, or degradation over time may deliver OCl⁻ rather than HOCl, which has substantially lower antimicrobial and anti-inflammatory potency.
HOCl disrupts bacterial cell membranes and denatures proteins through oxidative stress. Crucially, because it kills through physical disruption rather than enzymatic inhibition, it does not contribute to antibiotic resistance. It is bactericidal against Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, Cutibacterium acnes, and a range of fungi and viruses at appropriately calibrated concentrations. It also modulates pro-inflammatory pathways, including suppression of NF-κB signaling and reduction of metalloproteinase activity. A 2025 Biomedicines review found particularly strong evidence in treating conditions like acne vulgaris, atopic dermatitis (AD), seborrheic dermatitis, pruritus, wound ulcers, and diabetic ulcers.1
📊 POLL: When do you tell your patients to use their HOCl spray?
The Evidence
The critical product-quality problem lies in stability:
HOCl is chemically unstable in aqueous solution. It degrades over time through several pathways
The biological activity that clinical studies demonstrate is dependent on the HOCl molecule being present in active form at the right concentration and pH at the time of use.
Stabilized commercial HOCl products list 12 to 24 months sealed shelf life when stored correctly (below 25°C, in opaque containers, away from UV exposure).
After opening, consumer spray bottles degrade more rapidly (estimates of 30 to 90 days under typical conditions) due to air exchange through the spray mechanism, UV exposure, temperature fluctuations, and nozzle contamination.
Formulations with higher concentrations (500+ ppm) paradoxically degrade faster than moderate-concentration products (200–300 ppm).
The most promising indication has been demonstrated in acne treatment. A double-blind, placebo-controlled trial randomized 40 acne patients to apply 0.005% sodium hypochlorite (NaOCl — the precursor/analogue of HOCl in alkaline conditions) or placebo 3 times daily in a split-face design for 1 month. The total number of inflammatory lesions decreased significantly with active treatment.2 Existing bleach bath literature may also provide a foundation for AD treatment. For example, a 2017 study demonstrated that sodium hypochlorite 0.004% considerably decreased S. aureus load in AD lesions, a finding that directly informs HOCl spray's use as a more targeted, patient-friendly delivery format for the same chemistry.3 These sprays have also seen wide adoption in aesthetic and surgical dermatology practices, particularly for post-procedures (lasers, peels, biopsies, and more).
HOCl's longest clinical track record is in wound care. The WHO's 2025 Essential Medicines List documentation for HOCl confirms that at least eight branded aqueous HOCl formulations have received FDA 510(k) clearance for topical wound management over the past decade.4 In a 2015 study of epidermolysis bullosa patients, daily HOCl spray application for 8 weeks reduced S. aureus colonization, promoted wound healing, and restored microbiome diversity in a population with notoriously refractory chronic wounds.5
The most dramatic claim on social media is that HOCl "completely clears" acne on its own and can replace prescriptions and systemic therapies for inflammatory disease. These are not supported by any literature; HOCl has no evidence in severe acne, nodulocystic disease, or as monotherapy in place of established agents. And although the case is mechanistically plausible for the treatment of rosacea and seborrheic dermatitis, dedicated evidence is currently limited.
HOCl is not a gimmick. It is an endogenous innate immune molecule with genuine antimicrobial, anti-inflammatory, and wound-healing properties documented across clinical studies. Its resistance-sparing kill mechanism, favorable tolerability profile relative to conventional antiseptics, and broad pathogen coverage give it a legitimately differentiated profile. For wound care, post-procedure skin, and adjunctive use in AD and acne, the dermatologic evidence base is real and clinically relevant.
The social media claims, however, outpace the evidence substantially. The largest acne trial in this space is a small, single-center split-face study of 40 patients using NaOCl. Rosacea evidence is anecdotal and superiority to established treatments (tretinoin, benzoyl peroxide, topical retinoids, biologics) is unsupported. And the critical missing conversation—product quality, concentration, stability, and storage—is entirely absent from the influencer content that is driving adoption.
The Script
If a patient comes in with questions about their HOCl spray routine, here are some important points to hit:
Use it as an adjunct: The data does support HOCl’s killing of acne-causing bacteria, but it's not potent enough as a standalone to replace a retinoid, benzoyl peroxide, or other proven therapies.
Choose the right product: Ensure that the formulation is active, stable, and properly concentrated. It should also list the concentration in ppm, come in an opaque bottle, and have FDA clearance for skin use.
Store it properly: Keep the bottle away from heat and light, and make sure that you're replacing it within the post-opening window.
Recommend for post-procedural use: HOCl is antimicrobial and doesn't damage healing skin cells the way alcohol-based products can. A daily mist covers bacteria without impairing the repair process.
References
1. Haralović V, Mokos M, Špoljar S, et al. Hypochlorous acid: clinical insights and experience in dermatology, surgery, dentistry, ophthalmology, rhinology, and other specialties. Biomedicines. 2025;13(12):2921. doi:10.3390/biomedicines13122921
2. Dorostkar A, Ghahartars M, Namazi M, et al. Sodium hypochlorite 0.005% versus placebo in the treatment of mild to moderate acne: a double-blind randomized controlled trial. Dermatol Pract Concept. 2021;11(3):e2021046. doi:10.5826/dpc.1103a46
3. Eriksson S, van der Plas MJA, Mörgelin M, Sonesson A. Antibacterial and antibiofilm effects of sodium hypochlorite against Staphylococcus aureus isolates derived from patients with atopic dermatitis. Br J Dermatol. 2017;177(2):513–521.
4. WHO Expert Committee on the Selection and Use of Essential Medicines. Hypochlorous acid (HOCl): application for inclusion on the WHO Essential Medicines List. Geneva: WHO; 2025.
5. Zhou XA, Burns MB, Ren Z, et al. An acid-oxidising solution containing hypochlorous acid reduces Staphylococcus aureus and improves bacterial diversity in epidermolysis bullosa wounds. Exp Dermatol. 2025;34(8):e70147. doi:10.1111/exd.70147
